PT  - JOURNAL ARTICLE
AU  - Johann, Pascal
AU  - Lenz, Dominic
AU  - Ries, Markus
TI  - “The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”
AID  - 10.1101/2021.01.01.21249120
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.01.21249120
4099  - http://medrxiv.org/content/early/2021/01/04/2021.01.01.21249120.short
4100  - http://medrxiv.org/content/early/2021/01/04/2021.01.01.21249120.full
AB  - Background Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest.Objectives To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM.Methods Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database between 1983 and 2020. STROBE criteria were respected.Results Four orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treatment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations were subsequently withdrawn for unknown reasons. The number of orphan drug designations per year shows a growing trend. In the last decade, the therapeutic mechanism of action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs (median year of designation 2008) to immunotherapeutic approaches and small molecules (median year of designation 2014 and 2015 respectively) suggesting an increased focus on precision in the therapeutic mechanism of action for compounds the development pipeline.Conclusion Despite the fact that current pharmacological treatment options in GBM are sparse, the drug development pipeline is steadily growing. In particular, the surge of designated immunotherapies detected in the last years raises the hope that elaborate combination possibilities between classical therapeutic backbones (radiotherapy) and novel, currently experimental therapeutics may help to provide better therapies for this deadly disease in the future.Strengths and limitationsThis study provides a quantitative overview on the drug development pipeline for pediatric and adult oncology in general and specifically for the indication glioblastomaAnalyzing the therapeutic mechanisms of designated compounds in glioblastoma reveals an increased focus on personalized and targeted therapiesThe precise reasons for failure of approved drugs and for withdrawal of approved drugs in glioblastoms are unknownFor the analysis, only the databases “FDALabel” (https://nctr-crs.fda.gov/fdalabel/ui/search) and the FDA Orphan drug product designation database (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/) were consideredCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or non-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University Hospital HeidelbergAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article or uploaded as supplementary infor-mation. All data relevant to the study are included in the article.ALLAcute lymphoblastic leukemiaAMLAcute myeloid leukemiaCARChimeric antigen receptorCLLChronic lymphocytic leukemiaEGFREpidermal growth factor receptorFDAFood and drug administrationGBMGlioblastomaGISTGastrointestinal stroma tumorGVHGraft versus host diseaseHCCHepatocellular carcinomaHLHemophagocytic lymphhistiocytosisMBMedulloblastomaMDSMyelodysplastic syndromeMGMTMethylguaninmethyltransferaseMPNMyeloproliferative neoplasiaNCNasopharyngeal carcinomaNTRKNeurotrophic tyrosine kinasePNHParoxysmal nightly heomglobinuriaSCDSickle cell diseaseVEGFVasoendothelial growth factor